There is mixed trial evidence concerning the use of low molecular weight heparin (LMWH) in patients with acute ischaemic stroke.
Some trials suggest a reduction in mortality/dependency at six months in those treated with LMWH.
However recent evidence suggests that LMWH has no significant benefit over aspirin for acute ischaemic stroke in patients with atrial fibrillation.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.